FATE THERAPEUTICS INC Operating Expenses
FATE THERAPEUTICS INC (FATE) reported Operating Expenses of $33.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- FATE THERAPEUTICS INC operating expenses for the quarter ending 2026-06-30 was $33.22M, a 14.56% decline year-over-year.
- FATE THERAPEUTICS INC operating expenses for the quarter ending 2026-03-31 was $34.30M, a 20.07% decline year-over-year.
- FATE THERAPEUTICS INC operating expenses for the quarter ending 2025-12-31 was $36.09M, a 43.26% decline year-over-year.
- FATE THERAPEUTICS INC operating expenses for the quarter ending 2025-09-30 was $36.48M, a 34.22% decline year-over-year.
- FATE THERAPEUTICS INC operating expenses for fiscal 2025 was $154.35M, a 31.07% decline from fiscal 2024.
- FATE THERAPEUTICS INC operating expenses for fiscal 2024 was $223.91M, a 11.86% decline from fiscal 2023.
- FATE THERAPEUTICS INC operating expenses for fiscal 2023 was $254.04M, a 37.22% decline from fiscal 2022.
- FATE THERAPEUTICS INC operating expenses for fiscal 2022 was $404.69M, a 48.32% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 77 month | Operating Expenses 80 month | Operating Expenses 83 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.22M 10-Q · filed 2026-08-13 | $67.52M 10-Q · filed 2026-08-13 | $103.61M derived: sum of 3 quarters · filed 2026-08-13 | $140.08M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $34.30M 10-Q · filed 2026-05-13 | $70.39M derived: sum of 2 quarters · filed 2026-05-13 | $106.86M derived: sum of 3 quarters · filed 2026-05-13 | $145.74M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $36.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $72.57M derived: sum of 2 quarters · filed 2026-02-26 | $111.44M derived: sum of 3 quarters · filed 2026-08-13 | $154.35M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $36.48M 10-Q · filed 2025-11-13 | $75.35M derived: sum of 2 quarters · filed 2026-08-13 | $118.26M 10-Q · filed 2025-11-13 | $181.87M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $38.88M 10-Q · filed 2026-08-13 | $81.78M 10-Q · filed 2026-08-13 | $145.39M derived: sum of 3 quarters · filed 2026-08-13 | $200.84M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $42.91M 10-Q · filed 2026-05-13 | $106.52M derived: sum of 2 quarters · filed 2026-05-13 | $161.97M derived: sum of 3 quarters · filed 2026-05-13 | $213.82M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $63.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $119.06M derived: sum of 2 quarters · filed 2026-02-26 | $170.91M derived: sum of 3 quarters · filed 2026-02-26 | $223.91M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $55.45M 10-Q · filed 2025-11-13 | $107.31M derived: sum of 2 quarters · filed 2025-11-13 | $160.30M 10-Q · filed 2025-11-13 | $210.05M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $51.85M 10-Q · filed 2025-08-12 | $104.85M 10-Q · filed 2025-08-12 | $154.60M derived: sum of 3 quarters · filed 2025-08-12 | $207.82M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $52.99M 10-Q · filed 2025-05-13 | $102.74M derived: sum of 2 quarters · filed 2025-05-13 | $155.97M derived: sum of 3 quarters · filed 2025-05-13 | $219.47M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $49.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $102.97M derived: sum of 2 quarters · filed 2025-03-05 | $166.47M derived: sum of 3 quarters · filed 2025-03-05 | $254.04M 10-K · filed 2025-03-05 | |||
| 2023-09-30 | $53.22M 10-Q · filed 2024-11-12 | $116.72M derived: sum of 2 quarters · filed 2024-11-12 | $204.29M 10-Q · filed 2024-11-12 | $313.07M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $63.50M 10-Q · filed 2024-08-13 | $151.07M 10-Q · filed 2024-08-13 | $259.85M derived: sum of 3 quarters · filed 2024-08-13 | $361.22M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $87.57M 10-Q · filed 2024-05-09 | $196.35M derived: sum of 2 quarters · filed 2024-05-09 | $297.72M derived: sum of 3 quarters · filed 2024-05-09 | $399.38M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $108.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $210.15M derived: sum of 2 quarters · filed 2024-02-26 | $311.81M derived: sum of 3 quarters · filed 2024-02-26 | $404.69M 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $101.37M 10-Q · filed 2023-11-08 | $203.03M derived: sum of 2 quarters · filed 2023-11-08 | $295.91M 10-Q · filed 2023-11-08 | $382.36M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $101.66M 10-Q · filed 2023-08-08 | $194.54M 10-Q · filed 2023-08-08 | $280.99M derived: sum of 3 quarters · filed 2023-08-08 | $349.84M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | $92.88M 10-Q · filed 2023-05-03 | $179.33M derived: sum of 2 quarters · filed 2023-05-03 | $248.18M derived: sum of 3 quarters · filed 2023-05-03 | $308.37M derived: sum of 4 quarters · filed 2023-05-03 | |||
| 2021-12-31 | $86.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $155.30M derived: sum of 2 quarters · filed 2023-02-28 | $215.49M derived: sum of 3 quarters · filed 2023-02-28 | $272.84M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $68.85M 10-Q · filed 2022-11-03 | $129.04M derived: sum of 2 quarters · filed 2022-11-03 | $186.39M 10-Q · filed 2022-11-03 | $235.69M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $60.19M 10-Q · filed 2022-08-03 | $117.54M 10-Q · filed 2022-08-03 | $166.84M derived: sum of 3 quarters · filed 2023-02-28 | $205.88M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $57.35M 10-Q · filed 2022-05-04 | $106.65M derived: sum of 2 quarters · filed 2023-02-28 | $145.69M derived: sum of 3 quarters · filed 2023-02-28 | $179.86M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $49.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $88.34M derived: sum of 2 quarters · filed 2023-02-28 | $122.51M derived: sum of 3 quarters · filed 2023-02-28 | $159.52M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $39.05M 10-Q · filed 2021-11-04 | $73.22M derived: sum of 2 quarters · filed 2021-11-04 | $110.22M 10-Q · filed 2021-11-04 | $142.10M derived: sum of 4 quarters · filed 2021-11-04 | |||
| 2020-06-30 | $34.17M 10-Q · filed 2021-08-04 | $71.18M 10-Q · filed 2021-08-04 | $103.06M derived: sum of 3 quarters · filed 2021-08-04 | $132.61M derived: sum of 4 quarters · filed 2021-08-04 | |||
| 2020-03-31 | $37.01M 10-Q · filed 2021-05-05 | $68.89M derived: sum of 2 quarters · filed 2021-05-05 | $98.44M derived: sum of 3 quarters · filed 2021-05-05 | $125.34M derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | $31.88M 10-K · filed 2020-03-02 | $61.43M derived: sum of 2 quarters · filed 2020-11-05 | $88.33M derived: sum of 3 quarters · filed 2020-11-05 | $111.41M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $29.55M 10-Q · filed 2020-11-05 | $56.45M derived: sum of 2 quarters · filed 2020-11-05 | $79.53M 10-Q · filed 2020-11-05 | $97.93M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $26.90M 10-Q · filed 2020-08-05 | $49.98M 10-Q · filed 2020-08-05 | $68.38M derived: sum of 3 quarters · filed 2020-08-05 | $86.10M derived: sum of 4 quarters · filed 2020-08-05 | |||
| 2019-03-31 | $23.08M 10-Q · filed 2020-05-11 | $41.48M derived: sum of 2 quarters · filed 2020-05-11 | $59.20M derived: sum of 3 quarters · filed 2020-05-11 | $79.83M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $18.40M 10-K · filed 2020-03-02 | $36.12M derived: sum of 2 quarters · filed 2020-03-02 | $56.75M derived: sum of 3 quarters · filed 2020-03-02 | $71.83M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $17.72M 10-K · filed 2020-03-02 | $38.35M derived: sum of 2 quarters · filed 2020-03-02 | $53.43M 10-Q · filed 2019-11-05 | $66.70M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | $20.63M 10-K · filed 2020-03-02 | $35.71M 10-Q · filed 2019-08-06 | $48.98M derived: sum of 3 quarters · filed 2020-03-02 | $60.35M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $15.08M 10-K · filed 2020-03-02 | $28.35M derived: sum of 2 quarters · filed 2020-03-02 | $39.72M derived: sum of 3 quarters · filed 2020-03-02 | $50.31M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $13.27M 10-K · filed 2019-03-05 | $24.64M derived: sum of 2 quarters · filed 2019-03-05 | $35.23M derived: sum of 3 quarters · filed 2019-03-05 | $46.23M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $11.37M 10-K · filed 2019-03-05 | $21.96M derived: sum of 2 quarters · filed 2019-03-05 | $32.96M 10-Q · filed 2018-11-01 | $41.64M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-06-30 | $10.60M 10-K · filed 2019-03-05 | $21.59M 10-Q · filed 2018-08-06 | $30.27M derived: sum of 3 quarters · filed 2019-03-05 | $39.69M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-03-31 | $11.00M 10-K · filed 2019-03-05 | $19.68M derived: sum of 2 quarters · filed 2019-03-05 | $29.09M derived: sum of 3 quarters · filed 2019-03-05 | $38.13M derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2016-12-31 | $8.68M 10-K · filed 2018-03-05 | $18.10M derived: sum of 2 quarters · filed 2018-03-05 | $27.13M derived: sum of 3 quarters · filed 2018-03-05 | $36.37M 10-K · filed 2019-03-05 | |||
| 2016-09-30 | $9.41M 10-K · filed 2018-03-05 | $18.45M derived: sum of 2 quarters · filed 2018-03-05 | $27.68M 10-Q · filed 2017-11-01 | $35.67M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-06-30 | $9.03M 10-K · filed 2018-03-05 | $18.27M 10-Q · filed 2017-08-14 | $26.26M derived: sum of 3 quarters · filed 2018-03-05 | $33.61M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-03-31 | $9.24M 10-K · filed 2018-03-05 | $17.23M derived: sum of 2 quarters · filed 2018-03-05 | $24.58M derived: sum of 3 quarters · filed 2018-03-05 | $32.13M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2015-12-31 | $7.99M 10-K · filed 2017-03-16 | $15.34M derived: sum of 2 quarters · filed 2017-03-16 | $22.89M derived: sum of 3 quarters · filed 2017-03-16 | $30.21M 10-K · filed 2018-03-05 | |||
| 2015-09-30 | $7.35M 10-K · filed 2017-03-16 | $14.90M derived: sum of 2 quarters · filed 2017-03-16 | $22.23M 10-Q · filed 2016-11-07 | $28.17M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $7.55M 10-K · filed 2017-03-16 | $14.87M 10-Q · filed 2016-08-08 | $20.81M derived: sum of 3 quarters · filed 2017-03-16 | $26.80M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $7.32M 10-K · filed 2017-03-16 | $13.27M derived: sum of 2 quarters · filed 2017-03-16 | $19.25M derived: sum of 3 quarters · filed 2017-03-16 | $25.29M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $5.94M 10-K · filed 2016-03-03 | $11.93M derived: sum of 2 quarters · filed 2016-03-03 | $17.97M derived: sum of 3 quarters · filed 2016-03-03 | $24.90M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $5.98M 10-K · filed 2016-03-03 | $12.02M derived: sum of 2 quarters · filed 2016-03-03 | $18.96M 10-Q · filed 2015-11-03 | $23.86M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | $6.04M 10-K · filed 2016-03-03 | $12.98M 10-Q · filed 2015-08-05 | $17.88M derived: sum of 3 quarters · filed 2016-03-03 | $23.24M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | $6.94M 10-K · filed 2016-03-03 | $11.84M derived: sum of 2 quarters · filed 2016-03-03 | $17.20M derived: sum of 3 quarters · filed 2016-03-03 | $21.75M derived: sum of 4 quarters · filed 2016-03-03 | $94.63M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $4.90M 10-K · filed 2015-03-12 | $10.26M derived: sum of 2 quarters · filed 2015-03-12 | $14.82M derived: sum of 3 quarters · filed 2015-03-12 | $18.65M 10-K · filed 2016-03-03 | $87.70M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $5.36M 10-K · filed 2015-03-12 | $9.92M derived: sum of 2 quarters · filed 2015-03-12 | $13.74M 10-Q · filed 2014-11-12 | $18.43M derived: sum of 4 quarters · filed 2015-03-12 | $82.79M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $4.56M 10-K · filed 2015-03-12 | $8.39M 10-Q · filed 2014-08-12 | $13.07M derived: sum of 3 quarters · filed 2015-03-12 | $17.25M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-03-31 | $3.83M 10-K · filed 2015-03-12 | $8.52M derived: sum of 2 quarters · filed 2015-03-12 | $12.69M derived: sum of 3 quarters · filed 2015-03-12 | $16.52M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2012-12-31 | $4.69M 10-K · filed 2014-03-17 | $8.87M derived: sum of 2 quarters · filed 2014-03-17 | $12.69M derived: sum of 3 quarters · filed 2014-03-17 | $16.23M 10-K · filed 2015-03-12 | |||
| 2012-09-30 | $4.18M 10-K · filed 2014-03-17 | $8.00M derived: sum of 2 quarters · filed 2014-03-17 | $11.54M 10-Q · filed 2013-11-13 | ||||
| 2012-06-30 | $3.82M 10-K · filed 2014-03-17 | $7.36M derived: sum of 2 quarters · filed 2014-03-17 | |||||
| 2012-03-31 | $3.54M 10-K · filed 2014-03-17 | ||||||
| 2011-12-31 | $14.46M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |